Obesity, diabetes, and associated risk factors
The prevalence of obesity has increased in the past 10 years. Recent studies have associated obesity with other cardiovascular risk factors, and an increased risk of diabetes and cardiovascular death. Patients with obesity should undergo a global evaluation cardiovascular risk, including measurement of abdominal waist circumference, assessment of standard cardiovascular risk factors, screening for dyslipidemia, abnormal glucose metabolism, and hypertension. Recommendations for dietary modification should be tailored to the patient’s associated medical conditions, such as diabetes, dyslipidemia, and hypertension, and all patients should be instructed on the importance of monitoring caloric intake. For patients who can engage in regular physical activity, we recommend a minimum regimen of 150 min/wk of moderate intensity exercise, such as brisk walking. Use of pharmacotherapy for obesity can be considered when efforts at therapeutic lifestyle modification have been ineffective, but patients must be carefully screened because many agents have potential side effects. Surgical approaches for obesity have also been demonstrated to be effective in achieving and sustaining weight loss and improving markers of cardiovascular risk and should be considered in patients who are refractory to therapeutic lifestyle modification. All diabetic patients should be treated comprehensively to reduce other comorbid conditions, including hypertension and dyslipidemia. Hypoglycemic therapy should be initiated when efforts to reduce hyperglycemia to target thresholds fail.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 5.World Health Organization: Global strategy on diet, physical activity and health. http://www.who.int/gb/ ebwha/pdf_files/WHA57/A57_R17-en.pdf.Google Scholar
- 13.Hayman LL, Williams CL, Daniels SR, et al.: Cardiovascular health promotion in the schools. A statement for health and education professionals and child health advocates from the committee on atherosclerosis, hypertension, and obesity in youth of the council on cardiovascular disease in the young, American Heart Association. Circulation 2004, 110:2266–2275.PubMedCrossRefGoogle Scholar
- 17.GaedeP, Vedel P, Larsen N, et al.: Multinational intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393. The first randomized controlled trial to demonstrate an effect of hypoglycemic therapy on macrovascular events using a comprehensive approach of aggressive lipid lowering, blood pressure control, and a stepwise approach to hypoglycemic therapy.PubMedCrossRefGoogle Scholar
- 19.DansingerML, Gleason JA, Griffith JL, et al.: Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005, 293:43–53. This randomized clinical trial compared the effect of four diet plans on weight loss and markers of cardiovascular risk, and found similar reductions among the diet plans. Compliance was suboptimal but change in cardiovascular risk factors was associated with compliance for all diet plans.PubMedCrossRefGoogle Scholar
- 21.Gibbons RJ, Balady GJ, Bricker JT, et al.: ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002, 106:1883–1892.PubMedCrossRefGoogle Scholar
- 22.Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403. Primary results of the US Diabetes Prevention Project that demonstrated a significant reduction in the incidence of diabetes through lifestyle modification.PubMedCrossRefGoogle Scholar
- 28.BuchwaldH, Avidor Y, Braunwald E, et al.: Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292:1724–1737. This meta-analysis summarizes 136 studies of patients undergoing bariatric surgery. Significant improvement of diabetes, weight loss, diabetes, hypertension, dyslipidemia, and other obesity-associated comorbidities was found.PubMedCrossRefGoogle Scholar
- 31.NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel [no authors listed]. Ann Intern Med 1991, 115:956–961.Google Scholar
- 35.YusufS, Gerstein H, Hoogwerf B, et al.: Ramipril and the development of diabetes. JAMA 2001, 286:1882–1885. A post hoc analysis from the HOPE (Heart Outcomes Prevention Evaluation) trial demonstrating a reduced risk of diabetes mellitus among patients prescribed ACEIs. This finding has been confirmed in many other ACEI and ARB studies and is being prospectively investigated in clinical trials.PubMedCrossRefGoogle Scholar
- 36.Novartis Pharmaceuticals USA: Novartis Announces Largest Diabetes and Cardiovascular Disease Prevention Trial with Starlix and Diovan. http:// www.pharma.us.novartis.com/newsroom/pressReleases/ releaseDetail.jsp?PRID=141.Google Scholar
- 37.ClinicalTrials.gov: The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial. http://www.clinicaltrials.gov/ct/show/NCT00095654.Google Scholar
- 38.GrundySM, Cleeman JI, Merz NB, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004, 110:277–239. The NCEP response to recent clinical trials demonstrating a benefit of aggressive lipid-lowering therapy. This summary supports the use of an optional LDL cholesterol goal of less than 70 mg/dL for high-risk patients, including those with diabetes.Google Scholar